KEYTRUDA (pembrolizumab) Drug Insight and Market Forecast – 2032

KEYTRUDA (pembrolizumab) Drug Insight and Market Forecast – 2032

“KEYTRUDA (pembrolizumab) Drug Insight and Market Forecast – 2032” report provides comprehensive insights about KEYTRUDA (pembrolizumab) for Metastatic Colorectal Cancer (mCRC) in the 7MM. A detailed picture of the KEYTRUDA (pembrolizumab) for Metastatic Colorectal Cancer in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the KEYTRUDA (pembrolizumab) for Metastatic Colorectal Cancer. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the KEYTRUDA (pembrolizumab) market forecast, analysis for Metastatic Colorectal Cancer in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Metastatic Colorectal Cancer.

Drug Summary

KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. The drug is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1, and PD-L2, thereby activating T lymphocytes, which may affect both tumor cells and healthy cells. There are currently more than 1,200 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. In June 2020, the US FDA approved KEYTRUDA for intravenous injection for the first-line treatment of patients with unresectable or Metastatic Microsatellite Instability-high (MSI-H) or Mismatch Repair Deficient (dMMR) CRC. The drug is the first immunotherapy approved for this patient population as a first-line treatment and is administered to patients without also giving them chemotherapy. The drug received the breakthrough designation for colorectal cancer.

Mechanism of Action

Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells inhibits T cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors, and signaling through this pathway can contribute to the inhibition of active T-cell immune surveillance of tumors. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the KEYTRUDA (pembrolizumab) description, mechanism of action, dosage and administration, research and development activities in Metastatic Colorectal Cancer.

Elaborated details on KEYTRUDA (pembrolizumab) regulatory milestones and other development activities have been provided in this report.

The report also highlights the KEYTRUDA (pembrolizumab) research and development activity in Metastatic Colorectal Cancer in detail across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around KEYTRUDA (pembrolizumab).

The report contains forecasted sales of KEYTRUDA (pembrolizumab) for Metastatic Colorectal Cancer till 2032.

Comprehensive coverage of the late-stage emerging therapies for Metastatic Colorectal Cancer.

The report also features the SWOT analysis with analyst views for KEYTRUDA (pembrolizumab) in Metastatic Colorectal Cancer.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

KEYTRUDA (pembrolizumab) Analytical Perspective by DelveInsight

In-depth KEYTRUDA (pembrolizumab) Market Assessment

This report provides a detailed market assessment of KEYTRUDA (pembrolizumab) in Metastatic Colorectal Cancer in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

KEYTRUDA (pembrolizumab) Clinical Assessment

The report provides the clinical trials information of KEYTRUDA (pembrolizumab) in Metastatic Colorectal Cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for Metastatic Colorectal Cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence KEYTRUDA (pembrolizumab) dominance.

Other emerging products for Metastatic Colorectal Cancer are expected to give tough market competition to KEYTRUDA (pembrolizumab) and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of KEYTRUDA (pembrolizumab) in Metastatic Colorectal Cancer.

Our in-depth analysis of the forecasted sales data of KEYTRUDA (pembrolizumab) from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the KEYTRUDA (pembrolizumab) in Metastatic Colorectal Cancer.

Key Questions

What is the product type, route of administration and mechanism of action of KEYTRUDA (pembrolizumab)?

What is the clinical trial status of the study related to KEYTRUDA (pembrolizumab) in Metastatic Colorectal Cancer and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the KEYTRUDA (pembrolizumab) development?

What are the key designations that have been granted to KEYTRUDA (pembrolizumab) for Metastatic Colorectal Cancer?

What is the forecasted market scenario of KEYTRUDA (pembrolizumab) for Metastatic Colorectal Cancer?

What are the forecasted sales of KEYTRUDA (pembrolizumab) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available in Metastatic Colorectal Cancer and how are they giving competition to KEYTRUDA (pembrolizumab) for Metastatic Colorectal Cancer?

Which are the late-stage emerging therapies under development for the treatment of Metastatic Colorectal Cancer?